इम्यूनोकॉम्प्रोमाइज्ड रोगियों और अन्य उच्च-जोखिम स्थितियों में गंभीर मपॉक्स का उपचार

References

• Those with severe disease (e.g., haemorrhagic disease, confluent lesions, sepsis, encephalitis, or other conditions requiring hospitalisation)
• Those who are immunocompromised (e.g., acquired immune deficiency syndrome with CD4 count <200 cells/µL, leukaemia, lymphoma, generalised malignancy, solid organ transplantation, therapy with alkylating agents, antimetabolites, radiation, tumour necrosis factor inhibitors, high-dose corticosteroids, hematopoietic stem cell transplant recipient <24 months post-transplant or ≥24 months but with graft-versus-host disease or disease relapse, or having autoimmune disease with immunodeficiency as a clinical component).
• Paediatric populations, particularly patients younger than 8 years of age.
• Those with one or more complications (e.g., secondary bacterial skin infection; gastroenteritis with severe nausea/vomiting, diarrhoea, or dehydration; bronchopneumonia; concurrent disease or other comorbidities).
• Tecovirimat is the preferred treatment for severe mpox.
• If expert clinical judgement determines a patient requires specific treatment for mpox, the preferred first option for drug treatment is tecovirimat.